| Schizophrenia
Cobenfy vs Uzedy
Side-by-side clinical, coverage, and cost comparison for schizophrenia.Deep comparison between: Cobenfy vs Uzedy with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsUzedy has a higher rate of injection site reactions vs Cobenfy based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Uzedy but not Cobenfy, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Cobenfy
Uzedy
At A Glance
Oral
Twice daily
Muscarinic agonist/antagonist combination
SC injection
Every 4-8 weeks
Atypical antipsychotic
Indications
- Schizophrenia
- Schizophrenia
- Bipolar I disorder
Dosing
Schizophrenia Starting dose 50 mg/20 mg orally twice daily for at least 2 days, then 100 mg/20 mg twice daily for at least 5 days; may increase to 125 mg/30 mg twice daily based on tolerability and response (maximum dose); take at least 1 hour before or 2 hours after a meal; do not open capsules. Geriatric patients: start at 50 mg/20 mg twice daily, maximum 100 mg/20 mg twice daily.
Schizophrenia Once monthly SC injection (50 mg, 75 mg, 100 mg, or 125 mg) or once every 2 months (100 mg, 150 mg, 200 mg, or 250 mg) based on equivalent daily oral risperidone dose (2-5 mg); initiate the day after last oral dose, no loading dose required.
Bipolar I disorder Once monthly SC injection (50 mg, 75 mg, or 100 mg) as monotherapy or adjunctive therapy to lithium or valproate, based on equivalent daily oral risperidone dose (2-4 mg); once every 2 months dosing is not recommended for this indication.
Contraindications
- Urinary retention
- Moderate (Child-Pugh Class B) or severe (Child-Pugh Class C) hepatic impairment
- Gastric retention
- History of hypersensitivity to COBENFY or trospium chloride
- Untreated narrow-angle glaucoma
- Known hypersensitivity to risperidone, its metabolite paliperidone, or any of its components
Adverse Reactions
Most common (>=5%) Nausea, dyspepsia, constipation, vomiting, hypertension, abdominal pain, diarrhea, tachycardia, dizziness, gastroesophageal reflux disease
Serious Urinary retention, liver enzyme elevations, increases in heart rate, angioedema
Postmarketing Chest pain, hypertensive crisis, palpitations, supraventricular tachycardia, syncope, gastritis, rash, rhabdomyolysis, confusion, delirium, hallucinations, somnolence, vision abnormal, angioedema, anaphylactic reaction, Stevens-Johnson syndrome (reported with trospium chloride component)
Most common (>5%) Parkinsonism, akathisia, dystonia, tremor, sedation, dizziness, anxiety, blurred vision, nausea, vomiting, upper abdominal pain, stomach discomfort, dyspepsia, diarrhea, salivary hypersecretion, constipation, dry mouth, increased appetite, weight gain, fatigue, rash, nasal congestion, upper respiratory tract infection, nasopharyngitis, pharyngolaryngeal pain
Serious Increased mortality in elderly patients with dementia-related psychosis, cerebrovascular adverse events, neuroleptic malignant syndrome, tardive dyskinesia, metabolic changes, hyperprolactinemia, orthostatic hypotension and syncope, leukopenia, neutropenia, agranulocytosis, seizures, dysphagia, priapism
Postmarketing Alopecia, anaphylactic reaction, angioedema, atrial fibrillation, cardiopulmonary arrest, diabetic ketoacidosis, Stevens-Johnson syndrome and toxic epidermal necrolysis, sudden death, thrombocytopenia, injection site pain
Pharmacology
Xanomeline is a muscarinic agonist with preferential activity at M1 and M4 receptors in the central nervous system, where its efficacy in schizophrenia is thought to arise; trospium chloride is a peripheral muscarinic antagonist included to reduce cholinergic adverse effects.
Risperidone is an atypical antipsychotic whose therapeutic activity may be mediated through combined dopamine Type 2 (D2) and serotonin Type 2 (5HT2) receptor antagonism; clinical effect results from the combined concentrations of risperidone and its major active metabolite, 9-hydroxyrisperidone (paliperidone).
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Cobenfy
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (8/12) · Qty limit (11/12)
Uzedy
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (9/12)
UnitedHealthcare
Cobenfy
- Covered on 4 commercial plans
- PA (8/8) · Step Therapy (8/8) · Qty limit (2/8)
Uzedy
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Cobenfy
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (3/3)
Uzedy
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$0/fillfill
Cobenfy Copay Assistance ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableHealthWell: Movement Disorders - Medicare Access
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
CobenfyView full Cobenfy profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.